Drug Profile
Research programme: nicotinamide phosphoribosyltransferase inhibitor - Bayer
Alternative Names: Cmpd1; NAMPT inhibitors - BayerLatest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Bayer
- Class Small molecules
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Cancer in Germany (unspecified route) (Bayer pipeline, September 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in Germany
- 16 Apr 2016 Preclinical trials in Cancer in Germany (unspecified route) prior to April 2016